ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc (RXRX)

6.53
0.13
(2.03%)
Closed January 17 3:00PM
6.5895
0.0595
(0.91%)
After Hours: 6:58PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
6.5895
Bid
6.57
Ask
6.59
Volume
9,908,988
6.48 Day's Range 6.79
5.61 52 Week Range 15.74
Market Cap
Previous Close
6.40
Open
6.56
Last Trade
1
@
6.57
Last Trade Time
Financial Volume
US$ 65,567,995
VWAP
6.617
Average Volume (3m)
12,610,623
Shares Outstanding
286,640,833
Dividend Yield
-
PE Ratio
-5.71
Earnings Per Share (EPS)
-1.14
Revenue
44.58M
Net Profit
-328.07M

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery... Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
-
Recursion Pharmaceuticals Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker RXRX. The last closing price for Recursion Pharmaceuticals was US$6.40. Over the last year, Recursion Pharmaceuticals shares have traded in a share price range of US$ 5.61 to US$ 15.74.

Recursion Pharmaceuticals currently has 286,640,833 shares outstanding. The market capitalization of Recursion Pharmaceuticals is US$1.83 billion. Recursion Pharmaceuticals has a price to earnings ratio (PE ratio) of -5.71.

Recursion Pharmaceuticals (RXRX) Options Flow Summary

Overall Flow

Bearish

Net Premium

-22k

Calls / Puts

150.00%

Buys / Sells

40.00%

OTM / ITM

87.50%

Sweeps Ratio

0.00%

RXRX Latest News

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028 PR Newswire VANCOUVER, BC, Jan. 17, 2025 USA News Group News Commentary  Issued on behalf of Avant Technologies...

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028 Canada NewsWire VANCOUVER, BC, Jan. 17, 2025 USA News Group News Commentary  Issued on behalf of Avant Technologies...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.4105-5.8642857142977.0756.2136816026.5451036CS
40.56959.460132890376.028.665.93153697327.04963869CS
120.16952.640186915896.429.555.61126106236.98024275CS
26-1.7805-21.27240143378.379.555.6181866226.93750889CS
52-3.8105-36.639423076910.415.745.6170937238.22191261CS
156-7.1605-52.076363636413.7516.7454.5440154178.74386496CS
260-23.4105-78.0353042.814.5433794389.45963049CS

RXRX - Frequently Asked Questions (FAQ)

What is the current Recursion Pharmaceuticals share price?
The current share price of Recursion Pharmaceuticals is US$ 6.5895
How many Recursion Pharmaceuticals shares are in issue?
Recursion Pharmaceuticals has 286,640,833 shares in issue
What is the market cap of Recursion Pharmaceuticals?
The market capitalisation of Recursion Pharmaceuticals is USD 1.83B
What is the 1 year trading range for Recursion Pharmaceuticals share price?
Recursion Pharmaceuticals has traded in the range of US$ 5.61 to US$ 15.74 during the past year
What is the PE ratio of Recursion Pharmaceuticals?
The price to earnings ratio of Recursion Pharmaceuticals is -5.71
What is the cash to sales ratio of Recursion Pharmaceuticals?
The cash to sales ratio of Recursion Pharmaceuticals is 41.99
What is the reporting currency for Recursion Pharmaceuticals?
Recursion Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Recursion Pharmaceuticals?
The latest annual turnover of Recursion Pharmaceuticals is USD 44.58M
What is the latest annual profit for Recursion Pharmaceuticals?
The latest annual profit of Recursion Pharmaceuticals is USD -328.07M
What is the registered address of Recursion Pharmaceuticals?
The registered address for Recursion Pharmaceuticals is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Recursion Pharmaceuticals website address?
The website address for Recursion Pharmaceuticals is www.recursion.com
Which industry sector does Recursion Pharmaceuticals operate in?
Recursion Pharmaceuticals operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BTCTBTC Digital Ltd
US$ 8.2697
(73.73%)
61.45M
BDMDBaird Medical Investment Holdings Ltd
US$ 8.80
(62.36%)
18.63M
CRKNCrown Electrokinetics Corporation
US$ 0.1235
(54.96%)
764.86M
NUKKNukkleus Inc
US$ 29.97
(45.98%)
19.09M
GSITGSI Technology
US$ 3.97
(44.36%)
87.7M
DOGZDogness International Corporation
US$ 18.23
(-58.77%)
740.45k
ORKTOrangeKloud Technology Inc
US$ 3.02
(-24.88%)
21.08M
PMAXPowell Max Ltd
US$ 0.6364
(-23.31%)
4.17M
LGCBLinkage Global Inc
US$ 0.2876
(-22.27%)
890.66k
YYAIConnexa Sports Technologies Inc
US$ 0.8299
(-20.20%)
602.48k
CRKNCrown Electrokinetics Corporation
US$ 0.1235
(54.96%)
764.86M
GCTKGlucoTrack Inc
US$ 0.0852
(15.45%)
465.22M
RIMEAlgorhythm Holdings Inc
US$ 0.0406
(-4.02%)
387.23M
TGLTreasure Global Inc
US$ 0.2459
(14.75%)
267.1M
NVDANVIDIA Corporation
US$ 137.71
(3.10%)
201.4M

RXRX Discussion

View Posts
bwrbad bwrbad 3 days ago
believe in miracle ----- come to RXRX------
👍️0
TucsonPhil TucsonPhil 6 days ago
Looks like Lilly is late to the party.

https://www.statnews.com/2025/01/10/eli-lilly-andreessen-horowitz-500-million-venture-fund-ai-focus/
👍️0
bwrbad bwrbad 1 week ago
cursion-re-cursion in flame after FDA REC 3565 blessings
👍️0
bwrbad bwrbad 2 weeks ago
Gibson🤢🥵🥶😷Gibson
👍️0
bwrbad bwrbad 2 weeks ago
baby nvda
👍 1
bwrbad bwrbad 3 weeks ago
balding haircut at RXRX
👍️0
Monksdream Monksdream 4 weeks ago
RXRX, under $7
👍️0
bwrbad bwrbad 4 weeks ago
out for now, let CEO work his magic if he has one under his sleeve
👍️0
bwrbad bwrbad 1 month ago
is something wrong with RxRx, it looked promising based on what said to public. but something not right. ground shaken up. - like trouble.
what wrong with the CEO. if this continues that is bad sign for future of the company and the CEO.
👍️0
bwrbad bwrbad 1 month ago
RXRX
👍️0
bwrbad bwrbad 1 month ago
RxRx partnership: GOOG NVDA MSFT Roche/Genentech Bayer Bristol Myers Squibb Sanofi Merck ......
👍 1
bwrbad bwrbad 1 month ago
RxRx M&A: Valence –Cyclica - Exscientia
Valence – a leader in generative AI and deep learning models
Cyclica - a deep learning engine that predicts the polypharmacology of small molecules in drug discovery.
Exscientia - AI-driven precision medicine
RXRX - Regenerative AI - TechBio powerhouse
undergoing post merger reorganization, some job cuts
enough cash to fund through 2027
Ark Q3 2024 Stake: $215.9 million
Hedge Fund Investors Q3 2024:: 16
more than ten drugs in trials.
👍️0
bwrbad bwrbad 1 month ago
market up big and RxRx ignored,
if quantum computing which is 7-10 years away getting attention now, then this should be in the rocket heading for stratosphere.
👍️0
TucsonPhil TucsonPhil 1 month ago
RXRX seeing some promising results in early trials. Proof of concept will solidify belief in the platform.

If cost of trials can be reduced, by less attrition of candidates, then they should see more licensing agreements, and funding, from pharma companies IMO.
👍️ 1
bwrbad bwrbad 1 month ago
Revenue (ttm) 65.18M; Quarterly Revenue Growth (yoy) 147.60%
Total Cash (mrq) 427.65M; Total Debt (mrq) 90.62M
Shares Outstanding 6 388.94M; Float 8 252.42M
clinical trial : REC-994 in Phase 2, REC-2282 in Phase 2/3; few other in phase 1 and 2, all in less than 2 year not 15-18 years (conventional).

% Held by Institutions 1 69.40% Shares Short (Nov 15, 2024) 4 64.57M 25%
👍️ 1
JJ8 JJ8 1 month ago
Rxrx share price Long Tail Up since 06 Dec 2024.
👍️0
paperman paperman 1 month ago
Phase 1 news expected tonight at conference.
👍️0
paperman paperman 1 month ago
Phase 1 news expected tonight at conference.
👍️0
bwrbad bwrbad 1 month ago
this is one magnificent AI drug discovery platform - be household name like google tesla Microsoft ...
👍️0
JJ8 JJ8 1 month ago
Bought it yesterday at $6.60

Today it's up about 22%.

Same story with 2 other stocks and they all go up today more than 20%!

Whoa! IN CREDIBLE!
👍️0
TucsonPhil TucsonPhil 1 month ago
Agreed, but there will be wild swings, until they get their footing with clinical trials proving the concept works. Trade it until then, and keep one foot in the door for surprise announcements.
👍️0
bwrbad bwrbad 1 month ago
RxRx going to be top player in future pharma drug discovery
👍️0
TucsonPhil TucsonPhil 1 month ago
Good company, but MMs playing games this morning. Insider buying? News? Who knows? Missed this runup, but will wait for the dip again.
👍️0
bwrbad bwrbad 1 month ago
GOOG -- RxRx -- NVDA -- RxRx -- MSFT
👍️0
bwrbad bwrbad 1 month ago
agree but better, much bigger scope, on way to become a high flying company of the future
price target 150 in two year
👍️0
uksausage uksausage 1 month ago
no it is the PLTR of Drug discovery
both rely on NVDA to run fast
👍️0
bwrbad bwrbad 1 month ago
started buying little little- this is NVDA of DRUG DISCOVERY
👍️0
ToucanYoucan ToucanYoucan 1 month ago
$RXRX - That's why I'm planning to steadily accumulate shares - with the hope that one or more of these new treatments materializes.
👍️0
bwrbad bwrbad 1 month ago
high potential if delivers,
👍️0
TucsonPhil TucsonPhil 1 month ago
Good gains in past week, but looks like it is getting ready to drift lower again.
👍️0
TucsonPhil TucsonPhil 1 month ago
First patient dosed.

https://ir.recursion.com/news-releases/news-release-details/recursion-announces-first-patient-dosed-phase-12-clinical-study
👍️0
lambchops lambchops 2 months ago
Glad to see the uptick! Was beaten down for a while. Too good of stock to be down for long.

LC

RXRX
👍️ 1
ToucanYoucan ToucanYoucan 2 months ago
$RXRX - Having a huge day here!!
👍️0
ToucanYoucan ToucanYoucan 2 months ago
$RXRX - Nice move up today! This will take a little time to find its footing pps-wise after the merger...imo
👍️0
TucsonPhil TucsonPhil 2 months ago
Many foreign countries supplying pharmaceuticals to U.S. at exorbitant markups.

Will anything be done about that? I do not believe tariffs will help with that problem, since people either pay, whatever the cost, or suffer and die.
👍️0
Monksdream Monksdream 2 months ago
RXRX 10Q 11/6
👍️0
Monksdream Monksdream 3 months ago
RXRX under $10
👍️0
Monksdream Monksdream 3 months ago
RXRX under $10
👍️0
mick mick 3 months ago
👍️0
abrooklyn abrooklyn 4 months ago
https://x.com/RecursionPharma/status/1841453309342740925
👍️0
TucsonPhil TucsonPhil 4 months ago
So many clinical trials in work, but for this to translate to value, they will need to show high efficacy and a much shorter time-to-market, using Recursion platform. The problem may be that Recursion can identify promising candidates quickly, but the slow-moving follow-on processes will still eat up valuable time. The value proposition here is the decrease in attrition, for candidates that fail in early stage trials.

https://ir.recursion.com/news-releases/news-release-details/recursion-gives-guidance-seven-clinical-readouts-within-18

https://www.recursion.com/pipeline
👍️0
mick mick 4 months ago
WALL @ $7.5 , $7.0
👍️0
mick mick 4 months ago
https://www.stockscores.com/charts/charts/?ticker=RXRX
👍️0
lambchops lambchops 4 months ago
Yes. Good stock to put on watchlist IMO.
Still reasonably cheap. Check MACD.

LC

RXRX
👍️0
mick mick 4 months ago
diamond in the ruff

RXRX
Recursion Pharmaceuticals Inc
6.32
0.20 (3.27%)
Volume: 3,082,418
Day Range: 6.055 - 6.32
Last Trade Time: 4:28:47 PM EDT
👍️0
mick mick 4 months ago
RXRX
Recursion Pharmaceuticals Inc
5.95
-0.22 (-3.57%)
Volume: 4,577,882
Day Range: 5.895 - 6.30
Last Trade Time: 7:58:59 PM EDT
👍️0
lambchops lambchops 4 months ago
Yes, I've been adding shares of RXRX this week.

LC

RXRX
👍️0
TucsonPhil TucsonPhil 4 months ago
Looks.like a little dilution, but a good buying opportunity, to add some more.
👍️0
lambchops lambchops 4 months ago
Judging on the reaction some investors must not have liked it either.Will be a strong company into RXRX.I like buying good companies that have a downdraft. They usually come back strong.
Please note I own shares in this company.

LC

RXRX
👍️0
TucsonPhil TucsonPhil 4 months ago
I had not seen that merger announcement. Never came across in my broker news feed.
👍️0

Your Recent History

Delayed Upgrade Clock